Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW to Promptly Seek Expert Panel Discussion on Booster Shots: Minister
September 13, 2021
- Japan Should Arrange Boosters Immediately, Mix-and-Match Doses Too: LDP
September 10, 2021
- Regional Governors Club Urges Early Conclusion on HPV Vaccines
September 10, 2021
- COVID-19 Antibody Cocktail Given to 13,000 in Japan by August-End: MHLW
September 10, 2021
- Cabinet Counselor Koichi Ando Tapped as MHLW Economic Affairs Chief
September 8, 2021
- MHLW to Fund Avigan Program, COVID-19 Drugs from AZ, Shionogi
September 8, 2021
- Japan Strikes Deal for 150 Million Novavax Vaccine Doses, Supply Could Start Early Next Year
September 7, 2021
- Astellas’ Padcev, Pfizer’s JAK Inhibitor, AZ’s Lupus Drug Clear PAFSC Panel
September 7, 2021
- Pfizer Vaccine Imports Set to Be Completed in October: Minister
September 7, 2021
- MHLW Panel Backs Takeda’s Cell Therapy Darvadstrocel for Complex Anal Fistulas in CD
September 7, 2021
- Drug Makers Should Conduct Joint Inspections at Contract Manufacturers to Prevent GMP Violations: Expert
September 7, 2021
- Entresto Clears MHLW Panel with Strings Attached, It’s Not a 1st Choice Drug
September 6, 2021
- Japan Govt to Accelerate Discussion on Specific Growth Strategy
September 3, 2021
- Nationwide On-Site Inspections Identify GMP Issues at 9 Generic Plants: MHLW
September 3, 2021
- MHLW Panel to Review Entresto’s Hypertension Indication Again on September 3
September 3, 2021
- Healthcare Spending Totals 42.2 Trillion Yen in FY2020, Showing Record Drop of 1.4 Trillion Yen: MHLW
September 2, 2021
- LDP’s COVID-19 Headquarters Calls for Guidelines on Oral Steroid Administration to Patients Recuperating at Home
September 1, 2021
- Council to Discuss Resuming Active Recommendation of HPV Vaccines: Health Minister
September 1, 2021
- Japan’s Volume-Based Generic Share Reaches 82.1% at End of FY2020, 6 Prefectures Stalling Below 80%: MHLW
September 1, 2021
- MHLW Group Launches Study for Post-Marketing Safety Measures to Boost Global Harmonization, Efficiency
September 1, 2021
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…